Guidelines on the diagnosis and management of chronic lymphocytic leukaemia.

GUIDELINE TITLE
Guidelines on the diagnosis and management of chronic lymphocytic leukaemia.

BIBLIOGRAPHIC SOURCE(S)
Oscier D, Fegan C, Hillmen P, Illidge T, Johnson S, Maguire P, Matutes E, Milligan D, Guidelines Working Group of the UK CLL Forum, British Committee for Standards in Haematology. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol 2004 May;125(3):294-317. [169 references] PubMed

GUIDELINE STATUS
This is the current release of the guideline.

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

July 14, 2009 - Sirolimus (Rapamune), Cyclosporine (Sandimmune or Neoral and generics), Mycophenolate mofetil (Cellcept and generics), Mycophenolic acid (Myfortic): The U.S. Food and Drug Administration (FDA) is requiring the makers of certain immunosuppressant drugs to update their labeling to reflect that immunosuppressed patients are at increased risk for opportunistic infections, such as activation of latent viral infections, including BK virus-associated nephropathy.
September 11, 2008, Rituxan (Rituximab): Genentech informed healthcare professionals of revisions to prescribing information for Rituxan regarding a case of progressive multifocal leukoencephalopathy (PML) leading to death in a patient with rheumatoid arthritis who received Rituxan in a long-term safety extension clinical study.

abrir aquí para acceder al documento NGC AHRQ completo:
Guidelines on the diagnosis and management of chronic lymphocytic leukaemia.